Why the study?
Does an attenuated apathogenic reovirus vaccine protect chickens against viral arthritis/tenosynovitis challenge?
Does an attenuated apathogenic reovirus vaccine protect chickens against viral arthritis/tenosynovitis challenge?
An attenuated apathogenic reovirus vaccine safely and effectively protects chickens against viral arthritis/tenosynovitis.
Answers are grounded in this paper and cite their sources.
Attenuated reovirus vaccine protects challenged chicks from tenosynovitis; extends preclinical data but leaves open field efficacy in poultry.
A fully attenuated apathogenic reovirus vaccine was developed by 235 serial passages of S1133 strain avian reovirus in embryonating chicken eggs and 100 additional passages in chicken embryo fibroblast (CEF) cultures, 65 of which were cultured at 32 C. Chickens with and without maternal antibodies to avian reovirus were vaccinated subcutaneously at 1 day of age and challenged via footpad at 14 days of age. It appeared that the 40th, 66th, and 100th CEF passage levels were apathogenic at doses ranging from 10(2.5) to 10(6.8) TCID50/chick. No gross or microscopic lesions of tenosynovitis developed in vaccinated chicks. Vaccinated chicks were protected against challenge; unvaccinated control chickens were not.
No takes yet. Share an insight, caveat, or question.
Heide et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: